Skip to main content

Unable to load price data. Sorry.

¯\_(ツ)_/¯

Benda Pharmaceutical Inc. (NASDAQOTCBB:BPMA)

CAPS Rating: No stars

Unable to load market data for this Ticker. Sorry.

¯\_(ツ)_/¯

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

2 Outperform
0 Underperform
 

All-Star Players

1 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQOTCBB:BPMA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

Recent Community Commentary

Read the most recent pitches from players about BPMA.

Recs

0
Member Avatar Ssweet913 (92.44) Submitted: 11/2/2007 12:54:25 PM : Outperform Start Price: $2.42 NASDAQ OTC:BPMA Score: -264.41

Purchased this stock myself at $2.14, once people all over the world begin learning about Benda's successful gene therapy for cancer patients through the media and publications, demand will increase dramatically and this company will become a powerhouse in China.

Recs

0
Member Avatar chinaOTCplayer (< 20) Submitted: 10/31/2007 5:29:52 AM : Outperform Start Price: $2.78 NASDAQ OTC:BPMA Score: -259.09

This company has taken the lead in gene therapy for cancer treatment. Demand will spike.

Leaderboard

Find the members with the highest scoring picks in BPMA.

Score Leader

pushndaisies

pushndaisies (< 20) Score: +68.34

The Score Leader is the player with the highest score across all their picks in BPMA.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
chinaOTCplayer < 20 10/31/2007 Outperform 3Y $2.78 -100.00% +159.09% -259.09 1 Comment
Ssweet913 92.44 11/2/2007 Outperform 5Y $2.42 -100.00% +164.41% -264.41 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for BPMA.